We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
Current Opinion in Molecular Therapeutics 2010 December
Cancer treatment has undergone revolutionary changes during the past decade, as a result of the introduction of tyrosine kinase inhibitors (TKIs) that selectively inhibit growth factor pathways critical for tumor growth. Unexpected toxicity profiles and disappointing response rates to these 'magic bullets' have prompted research to identify markers that can predict toxicity or response to such agents. This review discusses the results of pharmacogenetic studies that have used germline DNA to assess the effects of various polymorphisms on currently available small-molecule TKIs. In these studies, polymorphisms in the EGFR gene (ie, EGFR CA-repeat and -216G>T) have consistently been associated with response to the EGFR-blocking TKIs gefitinib and, to a lesser extent, erlotinib. In addition, results from studies investigating polymorphisms in drug transporting enzymes (ie, ABCB1 1236T>C, 2677G>T/A and 3435C>T, and ABCG2 421C>A) suggest such polymorphisms are relevant for the pharmacokinetics of the TKIs; however, some conflicting findings on these polymorphisms have been published. The clinical impact of polymorphisms in EGFR and in drug transporting enzymes needs to be evaluated and validated in order for these pharmacogenetic markers to be applied successfully to individualize treatment in the clinic.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app